Details:
The agreement covers the registrations, trademarks, and related commercial rights of seven products, including four corticosteroids and one non-steroidal anti-inflammatory drug, across Europe and Emerging Markets.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Fidia Farmaceutici Spa
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment March 23, 2021
Details:
Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: OATO
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Phebra
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 29, 2023